MiMedx Group Inc(NASDAQ:MDXG) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during Pre-market on Jul 26, 2016. Company reported revenue of $57.34M. Analysts estimated a revenue of $56.31M. Earnings per share were $0.05. Analysts had estimated an EPS of $0.07.
MiMedx Group Inc (MDXG) made into the market gainers list on Fridays trading session with the shares advancing 0.54% or 0.04 points. Due to strong positive momentum, the stock ended at $7.49, which is also near the day’s high of $7.5. The stock began the session at $7.47 and the volume stood at 7,86,641 shares. The 52-week high of the shares is $12.48 and the 52 week low is $6.64. The company has a current market capitalization of $821 M and it has 10,95,48,431 shares in outstanding.
Several Insider Transactions has been reported to the SEC. On Jun 17, 2016, William Charles Taylor (President and COO) sold 24,333 shares at $7.52 per share price.Also, On May 23, 2016, Parker H Petit (CEO) purchased 20,000 shares at $6.99 per share price.On Nov 16, 2015, Charles Robert Evans (director) purchased 10,000 shares at $7.84 per share price, according to the Form-4 filing with the securities and exchange commission.
MiMedx Group Inc. (MiMedx) is an integrated developer manufacturer and marketer of regenerative biomaterial products and bioimplants processed from human amniotic membrane. The Company’s biomaterial platform technologies include AmnioFix and EpiFix its tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through its donor program mothers delivering full-term Cesarean section births can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. MiMedx processes the human amniotic membrane utilizing its Purion Process to produce an implant which is referred as an allograft. MiMedx is the supplier of amniotic tissue having supplied over 350000 allografts for application in the Wound Care Surgical Sports Medicine Ophthalmic and Dental sectors of healthcare. Its CollaFix technology combines a means of creating fibers from soluble collagen and a cross-linking process.